ADALIMUMAB

adalimumab 80 mg/0.8 mL injection, 0.8 mL syringe

ADALIMUMAB (12393G)

adalimumab 80 mg/0.8 mL injection, 0.8 mL syringe
12393G
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Complex refractory Fistulising Crohn disease
Treatment phase: Initial 1 (new patient or recommencement of treatment after a break in targeted therapy of more than 12 months)

Restriction

Indication: Complex refractory Fistulising Crohn disease
Treatment phase: Initial 2 (change or recommencement of treatment after a break in targeted therapy of less than 12 months)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 3 Max qty units: 3 # of repeats: 0 DPMQ: $2,042.73 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Humira
Yuflyma